IBD (Crohn’s disease and ulcerative colitis) involves chronic mucosal inflammation driven by dysregulated immune responses to gut microbiota, impaired intestinal barrier function, and excess Th1/Th17 cytokine production. Peptide research targets the mucosal healing deficit and immune dysregulation at the core of IBD pathology.
1. BPC-157 — Mucosal Healing / Fistula Repair
BPC-157 has the most compelling preclinical evidence for IBD — it heals intestinal fistulas, repairs damaged mucosa, normalizes gut motility, and reduces bowel wall inflammation in multiple Crohn’s and colitis animal models. It promotes angiogenesis in mucosal tissue and directly repairs tight junction integrity.
Dosing Protocol: 500 mcg oral BPC-157 (arginate form) daily, taken fasted. Stack with 250 mcg SubQ for systemic anti-inflammatory support. Cycle: 12 weeks minimum for IBD endpoints.
2. KPV — Intestinal NF-κB Suppression
KPV specifically targets NF-κB in intestinal epithelial cells and macrophages — the inflammatory signaling pathway most overactivated in IBD. It reduces mucosal IL-6, IL-8, and TNF-α, reducing the cytokine-driven mucosal damage characteristic of active IBD flares.
Dosing Protocol: 200–500 mcg oral (capsule for intestinal delivery) daily. Enema formulation for distal colitis. Cycle: 6–8 weeks.
3. VIP — Mucosal Immune Tolerance
VIP is an endogenous gut neuropeptide that promotes regulatory immune responses in gut-associated lymphoid tissue. In IBD, VIP signaling is deficient. Supplemental VIP reduces Th17-driven inflammation, promotes mucosal healing, and restores the immune tolerance to commensal bacteria that breaks down in IBD.
Dosing Protocol: 25–50 mcg SubQ daily, or via enema for targeted colonic delivery. Cycle: 4–6 weeks.
4. Thymosin Alpha-1 — Systemic Immune Normalization
IBD involves systemic immune dysregulation beyond the gut. Thymosin Alpha-1 normalizes the Th1/Th17 imbalance driving mucosal inflammation, promotes Treg expansion that mediates gut immune tolerance, and reduces the systemic inflammatory burden that perpetuates intestinal inflammation.
Dosing Protocol: 1.5 mg SubQ twice weekly for 4 weeks (induction), then weekly. Cycle: 12 weeks for IBD indication.
BPC-157 is the primary mucosal repair agent — directly healing the intestinal wall damage. KPV targets the NF-κB inflammatory cascade at the intestinal epithelial level. VIP restores the gut neuropeptide-immune regulation that is physiologically deficient in IBD. Thymosin Alpha-1 corrects the systemic immune dysregulation perpetuating the gut inflammation cycle.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).